

## Invitation to Swedencare AB (publ) Q3 2023 interim report presentation

The 25th of October at 7:30am CEST will Swedencare AB (publ) publish its report for the third quarter of 2023. A presentation of the report will be held the same day at 10:00am CEST via live webinar. The presentation will be available on the website at 9:00am CEST.

Swedencare invites shareholders and analysts to a presentation of the Q3 report where CEO Håkan Lagerberg and CFO Jenny Graflind will comment on the report. The presentation will be held at 10:00-10:30am CEST and can be followed via live webinar. The interim report will be published at 7:30am and will be available at www.swedencare.com.

The presentation will be held in English and after the presentation questions can be asked live via the webinar. No registration is needed.

Please use this link to join the webinar: <u>https://zoom.us/j/96109369393</u> After the presentation a recorded version will be available on our webpage.

## For more information, please contact:

Håkan Lagerberg, CEO Swedencare Phone: +46 (0)73 517 01 70 Email: hakan.lagerberg@swedencare.se

Jenny Graflind, CFO Swedencare Phone: +46 (0)73 944 85 54 Email: jenny.graflind@swedencare.se

FNCA is the Certified Adviser of the Company

Please visit the Company homepage www.swedencare.com

## About Swedencare

Swedencare, a listed company on NASDAQ First North Growth Market, specializes in pet healthcare and produces, markets and sells premium products in the global and fast-growing market. The company has a wide range of strong brands and products within most therapy areas, including Animal Pharmaceuticals®, Nutravet®, NutriScience, Pet MD®, Stratford®, VetWELL®, NaturVet® as well as ProDen PlaqueOff® for oral health to dogs and cats. Swedencare's headquarter is in Malmö, Sweden with subsidiaries located in nine countries with products sold in more than sixty countries. Swedencare's sales have increased significantly over the last few years with strong margins and profits.



## Attachments

Invitation to Swedencare AB (publ) Q3 2023 interim report presentation